Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Association of the polymorphisms of the genes APOC3 (rs2854116), ESR2 (rs3020450), HFE (rs1799945), MMP1 (rs1799750) and PPARG (rs1801282) with lipodystrophy in people living with HIV on antiretroviral therapy: a systematic review.

Tytuł:
Association of the polymorphisms of the genes APOC3 (rs2854116), ESR2 (rs3020450), HFE (rs1799945), MMP1 (rs1799750) and PPARG (rs1801282) with lipodystrophy in people living with HIV on antiretroviral therapy: a systematic review.
Autorzy:
da Silva AS; Faculdade de Ciências Médicas (FCM), Universidade de Pernambuco (UPE), Recife, PE, Brazil. .
Carvalho TL; Hospital Universitário Oswaldo Cruz (HUOC), Universidade de Pernambuco (UPE), Recife, PE, Brazil.
do Ó KP; Instituto de Pesquisa Aggeu Magalhães (CPqAM), Fundação Oswaldo Cruz (FIOCRUZ), Recife, PE, Brazil.
da Nóbrega DN; Instituto de Ciências Biológicas (ICB), Universidade de Pernambuco (UPE), Recife, PE, Brazil.
Dos Santos Souza R; Instituto de Ciências Biológicas (ICB), Universidade de Pernambuco (UPE), Recife, PE, Brazil.
da Silva Lima VF; Faculdade de Ciências Médicas (FCM), Universidade de Pernambuco (UPE), Recife, PE, Brazil.
Farias ICC; Faculdade de Ciências Médicas (FCM), Universidade de Pernambuco (UPE), Recife, PE, Brazil.
de Mendonça Belmont TF; Faculdade de Ciências Médicas (FCM), Universidade de Pernambuco (UPE), Recife, PE, Brazil.
de Mendonça Cavalcanti MDS; Faculdade de Ciências Médicas (FCM), Universidade de Pernambuco (UPE), Recife, PE, Brazil.
de Barros Miranda-Filho D; Faculdade de Ciências Médicas (FCM), Universidade de Pernambuco (UPE), Recife, PE, Brazil.
Źródło:
Molecular biology reports [Mol Biol Rep] 2020 Jun; Vol. 47 (6), pp. 4779-4787. Date of Electronic Publication: 2020 Apr 22.
Typ publikacji:
Journal Article; Systematic Review
Język:
English
Imprint Name(s):
Original Publication: Dordrecht, Boston, Reidel.
MeSH Terms:
HIV Infections/*genetics
HIV-Associated Lipodystrophy Syndrome/*genetics
HIV-Associated Lipodystrophy Syndrome/*metabolism
Apolipoprotein C-III/genetics ; Apolipoprotein C-III/metabolism ; Estrogen Receptor beta/genetics ; Female ; Gene Frequency ; Genetic Association Studies/methods ; Genotype ; HIV/drug effects ; HIV/pathogenicity ; Hemochromatosis Protein/genetics ; Hemochromatosis Protein/metabolism ; Humans ; Lipodystrophy/complications ; Lipodystrophy/genetics ; Male ; Matrix Metalloproteinase 1/genetics ; Matrix Metalloproteinase 1/metabolism ; PPAR gamma/genetics ; PPAR gamma/metabolism ; Polymorphism, Single Nucleotide
References:
Passaes CP, Sáez-Cirión A (2014) HIV cure research: advances and prospects. Virology 454(455):340–352. (PMID: 24636252)
Keetile M, Kgosidintsi G (2018) Sexual behaviours of HIV positive adults receiving HAART in Botswana: a cross sectional study. Afr Health Sci 18(3):503–511. (PMID: 306029816307016)
Ayele G, Tessema B, Amsalu A, Ferede G, Yismaw G (2018) Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAARTattending University of Gondar Referral Hospital Northwest Ethiopia. BMC Immunol 19(1):37. (PMID: 305585806296084)
Loonam CR, Mullen A (2012) Nutrition and the HIV-associated lipodystrophy syndrome. Nutr Res Rev 25(2):267–287. (PMID: 23174511)
Cherry CL, Lal L, Thompson KA et al (2005) Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 38(3):263–267. (PMID: 15735442)
Barbaro G, Barbarini G (2011) Human immunodeficiency virus & cardiovascular risk. Indian J Med Res 134(6):898–903. (PMID: 223108213284097)
Palios J, Kadoglou NP, Lampropoulos S (2012) The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines. Exp Diabetes Res 2012:103063. (PMID: 22203832)
Tsiodras S, Perelas A, Wanke C, Mantzoros CS (2010) The HIV-1/HAART associated metabolic syndrome—novel adipokines, molecular associations and therapeutic implications. J Infect 61:101–113. (PMID: 20547180)
Lazzaretti RK, Gasparotto AS, Sassi MG et al (2013) Genetic markers associated to dyslipidemia in HIV-infected individuals on HAART. ScientificWorldJournal 2013:608415. (PMID: 241911413804371)
Myerson M (2016) Lipid management in human immunodeficiency virus. Endocrinol Metab Clin North Am 45(1):141–169. (PMID: 26893003)
Soares FMG, Costa IMC (2011) Lipoatrofia facial associada ao HIV/AIDS: do advento aos conhecimentos atuais. An Bras Dermatol 86(5):843–864. (PMID: 22147023)
Belloso WH, Quirós R, Ivalo SA et al (2003) Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients. JAIDS 32(1):104–111. (PMID: 12514421)
Singhania R, Kotler D (2011) Lipodystrophy in HIV patients: its challenges and management approaches. HIV AIDS (Auckl) 3:135–143.
Troll JG (2011) Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. Curr Atheroscler Rep 13(1):51–56. (PMID: 21181310)
Veloso S, Peraire J, Viladés C et al (2010) Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients. Curr Pharm Des 16(30):3379–3389. (PMID: 20687887)
Mallon PWG (2006) Antiretroviral therapy and dyslipidemia: unlocking the code. PLoS Med 3(3):e85. (PMID: 164201041351918)
Wang QF, Liu X, O'Connell J et al (2004) Haplotypes in the APOA1-C3-A4-A5 gene cluster affect plasma lipids in both humans and baboons. Hum Mol Genet 13(10):1049–1056. (PMID: 15044382)
Dammerman M, Sandkuijl LA, Halaas JL et al (1993) An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 90(10):4562–4566. (PMID: 8099442)
Waterworth DM, Talmud PJ, Humphries SE et al (2001) Variable effects of the APOC3–482C %3e T variant on insulin, glucose and triglyceride concentrations in different ethnic groups. Diabetologia 44(2):245–248. (PMID: 11270684)
Guettier JM, Georgopoulos A, Tsai MY et al (2005) Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J Clin Endocrinol Metab 90(3):1705–1711. (PMID: 15598690)
Li WW, Dammerman MM, Smith JD et al (1995) Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may con-tribute to hypertriglyceridemia. J Clin Investig 96(6):2601–2605. (PMID: 8675624)
Aalto-Setala K, Fisher EA, Chen X et al (1992) Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Investig 90:1889–1900. (PMID: 1430212)
Pedersen SB, Bruun JM, Hube F et al (2001) Demonstration of estrogen receptor subtypes alpha and beta in human adipose tissue: influences of adipose cell differentiation and fat depot localization. Mol Cell Endocrinol 182(1):27–37. (PMID: 11500236)
Goulart AC, Zee RY, Pradhan A et al (2009) Associations of the estrogen receptors 1 and 2 gene polymorphisms with the metabolic syndrome in women. Metab Syndr Relat Disord 7(2):111–117. (PMID: 190320322674981)
Schüler S, Lattrich C, Skrzypczak M et al (2014) Polymorphisms in the promoter region of ESR2 gene and susceptibility to ovarian cancer. Gene 546(2):283–287. (PMID: 24881814)
Okura T, Koda M, Ando F, Niino N, Ohta S, Shimokata H (2003) Association of polymorphisms in the estrogen receptor alpha gene with body fat distribution. Int J Obes Relat Metab Disord 27(9):1020–1027. (PMID: 12917706)
Fox CS, Yang Q, Cupples LA et al (2005) Sex-specific association between estrogen receptoralpha gene variation and measures of adiposity: the Framingham Heart Study. J Clin Endocrinol Metab 90(11):6257–6262. (PMID: 16144952)
Almeida S, Hutz MH (2006) Estrogen receptor 1 gene polymorphisms and coronary artery disease in the Brazilian population. Braz J Med Biol Res 39(4):447–454. (PMID: 16612467)
Montosi G, Paglia P, Garuti C et al (2000) Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. Blood 96(3):1125–1129. (PMID: 10910932)
Bulaj ZJ, Griffen LM, Jorde LB et al (1996) Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 335(24):1799–1805. (PMID: 8943161)
Lagathu C, Eustace B, Prot M et al (2007) Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 12(14):498–500.
Singh H, Samani D, Nambiar N et al (2018) Effect of matrix metalloproteinase-21 (572C/T) polymorphism on HIV-associated neurocognitive disorder. APMIS 126(4):329–336. (PMID: 29575199)
Montes AH, Valle-Garay E, Suarez-Zarracina T et al (2010) The MMP1 (−16071G/2G) single nucleotide polymorphism associates with the HAART-related lipodystrophic syndrome. AIDS 24(16):2499–2505. (PMID: 20852404)
Brinckerhoff CE, Rutter JL, Benbow U (2000) Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6(12):4823–4830. (PMID: 11156241)
Vincenti MP, Brinckerhoff CE (2002) Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 4(3):157164.
Marion-Letellier R, Savoye G, Ghosh S (2016) Fatty acids, eicosanoids and PPAR gamma. Eur J Pharmacol 15(785):44–49.
Michalik L, Auwerx J, Berger JP et al (2006) International Union of Pharmacology LXI Peroxisome proliferator-activated receptors. Pharmacol Rev 58(4):726–741. (PMID: 17132851)
Stumvoll M, Haring H (2002) The peroxisome proliferator-activated receptor-gamma-2 Pro12Ala polymorphism. Diabetes 51(8):2341–2347. (PMID: 12145143)
Likanonsakul S, Rattanatham T, Feangvad S et al (2013) Polymorphisms in Fas gene is associated with HIV-related lipoatrophy in Thai patients. AIDS Res Hum Retroviruses 29(1):142–150. (PMID: 227750013537319)
Adams JN, Raffield LM, Freedman BI et al (2014) Analysis of common and coding variants with cardiovascular disease in the Diabetes Heart Study. Cardiovasc Diabetol 12(13):77.
Yu J, Wang H, Yang S et al (2010) The Effect of APOC3 promoter polymorphisms on the risk of hypertriglyceridemia in Chinese Han population with or without type 2 diabetes mellitus. Lab Med 41(1):34–39.
Pollex RL, Ban MR, Young TK et al (2007) Association between the -455T %3e C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample. BMC Med Genet 20(8):80–88.
Petersen KF, Dufour S, Hariri A et al (2010) Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 362(12):1082–1089. (PMID: 203355842976042)
Bonnet E, Bernard J, Fauvel J, Massip P et al (2008) Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients. AIDS Res Hum Retroviruses 24(2):169–171. (PMID: 18240956)
Poma B, Riva A, Nasi M, Cicconi P et al (2008) Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 22(14):1769–1778.
Gasparotto AS, Sprinz E, Lazzaretti RK et al (2012) Genetic polymorphisms in estrogen receptors and sexual dimorphism in fat redistribution in HIV-infected patients on HAART. AIDS 26(1):19–26. (PMID: 22011627)
Wu H, Xu L, Chen J, Hu J, Yu S, Hu G et al (2012) Association of estrogen receptor beta variants and serum levels of estradiol with risk of colorectal cancer: a case control study. BMC Cancer 12:276. (PMID: 227593473472165)
Tang L, Li J, Bao M, Xiang J, Chen Y, Wang Y (2018) Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis. Onco Targets Ther 11:1055–1066. (PMID: 295355315840274)
Chen L, Liang Y, Qiu J, Zhang L, Chen X, Luo X et al (2013) Significance of rs1271572 in the estrogenreceptor beta gene promoter and its correlation with breast cancer in a southwestern Chinese population. J Biomed Sci 20:32. (PMID: 237111513672062)
Pucci G, Alcidi R, Tap L, Battista F et al (2017) Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: a review of the literature. Pharmacol Res 120:34–42. (PMID: 28300617)
Hulgan T, Tebas P, Canter JA et al (2008) Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis 197(6):858–866. (PMID: 18419350)
Gaetano C, Massimo L, Alberto M (2010) Control of iron homeostasis as a key component of macrophage polarization. Haematologica 95(11):1801–1803. (PMID: 210373242966897)
Habib A, Finn AV (2014) The role of iron metabolism as a mediator of macrophage inflammation and lipid handling in atherosclerosis. Front Pharmacol 5:195. (PMID: 252215124145350)
Distante S, Elmberg M, Foss Haug KB et al (2003) Tumour necrosis fator alpha and its promoter polymorphisms role in the phenotypic expression of hemochromatosis. Scand J Gastroenterol 38(8):871–877. (PMID: 12940442)
Dongiovanni P, Fracanzani AL, Fargion S et al (2011) Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 55(4):920. (PMID: 21718726)
Kallianpur AS, Gerschenson M, Hulgan T, Kaur H et al (2018) Hemochromatosis (HFE) gene variants are associated with increased mitochondrial DNA levels during HIV-1 infection and antiretroviral therapy. AIDS Res Hum Retrov 34(11):942–949.
Jiang S, Yang ZH, Chen YY, He Z et al (2016) MMP-9 genetic polymorphism may confer susceptibility to COPD. Genet Mol Res 15(2):15026272.
Scherer S, de Souza TB, de Paoli J et al (2010) Matrix metalloproteinase gene polymorphisms in patients with rheumatoid arthritis. Rheumatol Int 30(3):369–373. (PMID: 19504098)
Ma MJ, Liu HC, Qu XQ, Wang JL (2015) Matrix metalloproteinase-3 gene polymorphism and its mRNA expression in rheumatoid arthritis. Genet Mol Res 14(4):15652–15659. (PMID: 26634533)
Bahrehmand F, Vaisi-Raygani A, Kiani A et al (2015) Matrix metalloproteinase 9 polymorphisms and systemic lupus erythematosus: correlation with systemic inflammatory markers and oxidative stress. Lupus 24(6):597–605. (PMID: 25416694)
Xu B, Xing RL, Zhang L et al (2019) Effects of MMP-1 1G/2G polymorphism on osteoarthritis: a meta-analysis study. Acta Orthop Traumatol Turc 53(2):129–133. (PMID: 306918746506809)
Parks WC, Wilson CL, López-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4(8):617–629. (PMID: 15286728)
Barak Y, Nelson MC, Ong ES et al (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4(4):585–595. (PMID: 10549290)
Saumoy M, Veloso S, Alonso-Villaverde C, HIV Lipodystrophy Study Group et al (2009) Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodystrophy. Curr HIV Res 7(5):533–540. (PMID: 19534662)
Majithia AR, Tsuda B, Agostini M, Gnanapradeepan K et al (2016) Prospective functional classification of all possible missense variants in PPARG. Nat Genet 48(12):1570–1575. (PMID: 277498445131844)
Rosen ED, Hsu C-H, Wang X, Sakai S et al (2002) C/EBPα induces adipogenesis through PPARγ: a unified pathway. Genes Dev 16(1):22–26. (PMID: 11782441155311)
Imai T, Takakuwa R, Marchand S, Dentz E et al (2004) Peroxisome proliferator-activated receptor γ is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci USA 101(13):4543–4547. (PMID: 15070754)
Contributed Indexing:
Keywords: APOC3; Antiretroviral therapy; ESR2; HFE; HIV; MMP1; PPARG; Polymorphisms
Substance Nomenclature:
0 (APOC3 protein, human)
0 (Apolipoprotein C-III)
0 (Estrogen Receptor beta)
0 (HFE protein, human)
0 (Hemochromatosis Protein)
0 (PPAR gamma)
0 (PPARG protein, human)
EC 3.4.24.7 (MMP1 protein, human)
EC 3.4.24.7 (Matrix Metalloproteinase 1)
Entry Date(s):
Date Created: 20200424 Date Completed: 20210216 Latest Revision: 20220311
Update Code:
20240105
DOI:
10.1007/s11033-020-05441-3
PMID:
32323264
Czasopismo naukowe
The aim of this study was to perform a systematic review to identify data reported in the literature concerning the association of APOC3 (rs2854116), ESR2 (rs3020450), HFE (rs1799945), MMP1 (rs1799750) and PPARG (rs1801282) polymorphisms with lipodystrophy in people living with HIV (PLWHIV) on antirretroviral therapy. The research was conducted in six databases and the studies were selected in two steps. First, a search was undertaken in the following electronic databases: PubMed, Science Direct, Medline, World Wide Science, Directory of Open Access Journals, Scielo, Lilacs and Medcarib. The titles and abstracts of 24,859 articles were read to select those that match the elegibilty criteria. Five papers that addressed the association of HAART, lipodystrophy and polymorphisms were selected for the review. There was no association between the polymorphisms of the genes APOC3 and PPARG and lipodystrophy. Another study described an association between the variant allele (G) of HFE and protection concerning the development of lipoatrophy (0.02) when compared with the reference allele (C). On the other hand, the variant allele (T) of the ESR2 gene was associated with the development of lipoatrophy (p = 0.007) when compared with the reference allele (C). In addition, the genotype and the variant allele of the gene MMP1 (2G) were associated with lipodystrophy in PLWHIV on HAART (p = 0.0002 and p = 0.0008, respectively). Therefore, further studies with other populations, involving PLWHIV on HAART are necessary to better understand the role of genetic markers, which may be involved in a predisposition to lipodystrophy.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies